110 related articles for article (PubMed ID: 2531855)
21. Stabilization of wild-type p53 in human T-lymphocytes transformed by HTLV-I.
Reid RL; Lindholm PF; Mireskandari A; Dittmer J; Brady JN
Oncogene; 1993 Nov; 8(11):3029-36. PubMed ID: 8414503
[TBL] [Abstract][Full Text] [Related]
22. Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes.
Sharma S; Schwarte-Waldhoff I; Oberhuber H; Schäfer R
Cell Growth Differ; 1993 Oct; 4(10):861-9. PubMed ID: 8274455
[TBL] [Abstract][Full Text] [Related]
23. Partially transformed T3T3 cells express high levels of mutant p53 in the 'wild-type' immunoreactive form with defective oligomerization.
Milner J; Chan YS; Medcalf EA; Wang Y; Eckhart W
Oncogene; 1993 Jul; 8(7):2001-8. PubMed ID: 8510941
[TBL] [Abstract][Full Text] [Related]
24. Several mutant p53 proteins detected in cancer-prone families with Li-Fraumeni syndrome exhibit transdominant effects on the biochemical properties of the wild-type p53.
Srivastava S; Wang S; Tong YA; Pirollo K; Chang EH
Oncogene; 1993 Sep; 8(9):2449-56. PubMed ID: 8361758
[TBL] [Abstract][Full Text] [Related]
25. Correlation between the conformational phenotype of p53 and its subcellular location.
Zerrahn J; Deppert W; Weidemann D; Patschinsky T; Richards F; Milner J
Oncogene; 1992 Jul; 7(7):1371-81. PubMed ID: 1620550
[TBL] [Abstract][Full Text] [Related]
26. Wild type p53 functions as a control protein in the differentiation pathway of the B-cell lineage.
Aloni-Grinstein R; Zan-Bar I; Alboum I; Goldfinger N; Rotter V
Oncogene; 1993 Dec; 8(12):3297-305. PubMed ID: 8247532
[TBL] [Abstract][Full Text] [Related]
27. Analysis of oncogene, tumor suppressor gene, and chromosomal alterations in HeLa x osteosarcoma somatic cell hybrids.
Isfort RJ; Cody DB; Lovell GJ; Gioeli D; Weissman BE; Doersen CJ
Mol Carcinog; 1999 May; 25(1):30-41. PubMed ID: 10331742
[TBL] [Abstract][Full Text] [Related]
28. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro.
Ozbun MA; Jerry DJ; Kittrell FS; Medina D; Butel JS
Cancer Res; 1993 Apr; 53(7):1646-52. PubMed ID: 8453637
[TBL] [Abstract][Full Text] [Related]
29. Mutant human tumor suppressor p53 modulates the activation of mitogen-activated protein kinase and nuclear factor-kappaB, but not c-Jun N-terminal kinase and activated protein-1.
Gulati AP; Yang YM; Harter D; Mukhopadhyay A; Aggarwal BB; Benzil DL; Whysner J; Albino AP; Murali R; Jhanwar-Uniyal M
Mol Carcinog; 2006 Jan; 45(1):26-37. PubMed ID: 16267831
[TBL] [Abstract][Full Text] [Related]
30. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome.
Malkin D; Chilton-MacNeill S; Meister LA; Sexsmith E; Diller L; Garcea RL
Oncogene; 2001 Jul; 20(33):4441-9. PubMed ID: 11494139
[TBL] [Abstract][Full Text] [Related]
31. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
32. Tumor suppressor p53 gene forms multiple isoforms: evidence for single locus origin and cytoplasmic complex formation with heat shock proteins.
Selkirk JK; He C; Patterson RM; Merrick BA
Electrophoresis; 1996 Nov; 17(11):1764-71. PubMed ID: 8982609
[TBL] [Abstract][Full Text] [Related]
33. Sensitization and caffeine potentiation of cisplatin cytotoxicity resulting from introduction of wild-type p53 gene in human osteosarcoma.
Tsuchiya H; Mori Y; Ueda Y; Okada G; Tomita K
Anticancer Res; 2000; 20(1A):235-42. PubMed ID: 10769661
[TBL] [Abstract][Full Text] [Related]
34. Frequency and structure of p53 rearrangements in human osteosarcoma.
Miller CW; Aslo A; Tsay C; Slamon D; Ishizaki K; Toguchida J; Yamamuro T; Lampkin B; Koeffler HP
Cancer Res; 1990 Dec; 50(24):7950-4. PubMed ID: 2253237
[TBL] [Abstract][Full Text] [Related]
35. Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.
Raycroft L; Wu HY; Lozano G
Science; 1990 Aug; 249(4972):1049-51. PubMed ID: 2144364
[TBL] [Abstract][Full Text] [Related]
36. [A possible role of phosphoprotein p53 in the mechanism of autostimulation of tumor cell proliferation].
Ageenko AI; Erkhov VS; Cherniaev LV; Volkova LIu
Eksp Onkol; 1990; 12(1):35-7. PubMed ID: 1688763
[TBL] [Abstract][Full Text] [Related]
37. p53--a candidate antioncogene.
Ross DW
Arch Pathol Lab Med; 1990 Apr; 114(4):432. PubMed ID: 2138881
[No Abstract] [Full Text] [Related]
38. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.
Finlay CA; Hinds PW; Tan TH; Eliyahu D; Oren M; Levine AJ
Mol Cell Biol; 1988 Feb; 8(2):531-9. PubMed ID: 2832726
[TBL] [Abstract][Full Text] [Related]
39. Mutagen test.
Sommer SS
Nature; 1990 Jul; 346(6279):22-3. PubMed ID: 2142254
[No Abstract] [Full Text] [Related]
40. Nucleotide sequence of a cDNA encoding the monkey cellular phosphoprotein p53.
Rigaudy P; Eckhart W
Nucleic Acids Res; 1989 Oct; 17(20):8375. PubMed ID: 2530498
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
